Skip to main content
OpenTrials
Completed

NCT Number: NCT02412423

Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors

In "beijing model" for haploidentical transplant, the rate of acute graft-versus-host disease (GVHD) from maternal or collateral donors was significantly higher than that from other kins. To reduce the GVHD incidence from maternal or collateral donors, post-transplantation cyclophosphamide is planned to be added into the protocol in "beijing model".

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Peking University People's Hospital

Beijing, 100044, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • haploidentical patients from maternal or collateral donors

Exclusion criteria

  • uncontrolled infection before transplant

Treatment and study plan

post-transplantation cyclophosphamide

Drug

Primary outcomes

  1. rate of acute GVHD

    Time frame: participants will be followed for an expected average of 365 days

Secondary outcomes

  1. rate of non-relapse mortality

    Time frame: participants will be followed for an expected average of 365 days

  2. rate of relapse

    Time frame: participants will be followed for an expected average of 365 days

  3. probability of survival

    Time frame: participants will be followed for an expected average of 365 days

Sponsors and collaborators

Lead sponsor

Peking University People's Hospital

Other

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2017
First posted
Apr 9, 2015
Registry last updated
Sep 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.